
|Articles|June 5, 2006
GPhA lauds FDA approval of Omnitrope
The Generic Pharmaceutical Association (GPhA) called the approvalof Sandoz Pharmaceutical's Omnitrope human growth hormone (HGH) asignificant first step in bringing more affordablebiopharmaceuticals to the U.S. marketplace. GPhA president/CEOKathleen Jaeger said that FDA's Omnitrope decision demonstratesthat sound science exists to support the approval of genericbiopharmaceuticals.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
2
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
3
Pharmacies Should Be Proactive in Expanding Clinical Services, Reimbursement Pathways | NCPA 2025
4
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
5


























































































































































